Anaptysbio, Inc (ANAB) Stock Analysis and Metrics

Anaptysbio

NASDAQ: ANAB

$54.15 ▼ -0.76 (-1.38%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.55 Bn

P/E-59.29

P/S8.98

Div. Yield0.00

Revenue Growth (1y) (Qtr)-7.98

Add ratio to table…

About

Anaptysbio Inc is a clinical stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The company develops antibody based product candidates that target key immune pathways to modify disease activity. Its pipeline includes rosnilimab ANB033 and ANB101 which are in various stages of clinical testing for conditions such as rheumatoid arthritis celiac disease eosinophilic esophagitis and other autoimmune indications.

Anaptysbio generates revenue primarily from milestone payments and royalties under its collaboration with GSK for the immuno oncology antibody Jemperli. The company also receives license and transition services revenue from its partnership with Vanda for the IL 36R antagonist imsidolimab. In addition it has received upfront payments and milestones from these collaborations which are recognized as revenue when achieved.

Anaptysbio occupies a niche in the biotechnology sector as a developer of novel antibody therapies that target specific immune cell populations involved in autoimmunity and inflammation. Its lead candidate rosnilimab differentiates itself by selectively depleting pathogenic T cells while sparing beneficial immune cells a mechanism not shared by many existing rheumatoid arthritis therapies such as anti TNF agents IL 6 inhibitors CTLA 4 fusion proteins or JAK inhibitors. For celiac disease and eosinophilic esophagitis ANB033 offers an approach that blocks IL 15 and IL 2 signaling through the CD122 subunit competing with agents like FB 102 GIA632 and TEV 53408. ANB101 targets plasmacytoid dendritic cells via BDCA2 modulation providing a distinct mechanism compared with litifilimab and other experimental molecules in lupus pathways. The company’s competitive advantages stem from its proprietary antibody engineering platform its deep understanding of immunological targets and the early clinical evidence showing target engagement and biological activity.

The company’s primary customers are its collaboration partners GSK and Vanda with whom it earns royalties milestone payments and license fees. Additionally Anaptysbio aims to serve patients suffering from autoimmune and inflammatory diseases through the future commercialization of its product candidates.

Investment Thesis

▲ Bull case

AnaptysBio (ANAB) holds a strategically valuable royalty interest in Jemperli through its 2014 agreement with Tesaro (now GSK Oncology), which entitles it to tiered royalties ranging from 8% on annual net sales below $1 billion to 25% on sales exceeding $2.5 billion, with payments continuing at least until key patents expire in 2035 in the U.S. and 2036 in the EU. Despite the ongoing legal dispute, Jemperli has demonstrated strong commercial momentum in oncology, particularly in endometrial cancer, with recent data showing continued adoption in both monotherapy and combination regimens, suggesting that sales are likely to grow significantly over the next several years. Given that GSK has not disputed the validity of the royalty structure in its filings and continues to commercialize Jemperli globally, the legal challenge appears to be a negotiating tactic rather than a fundamental threat to the underlying agreement, meaning ANAB is likely to retain its right to receive royalties regardless of the litigation outcome. The market may be underestimating the long-term cash flow potential from this asset, especially if Jemperli achieves blockbuster status — at $2 billion in annual net sales, ANAB would receive approximately $240 million annually in royalties (12% on the first $1B and 20% on the next $1B), a figure that could grow further with label expansions into other PD-1 responsive tumors such as microsatellite instability-high (MSI-H) cancers or gastric cancer, which are actively being explored in GSK’s pipeline. Furthermore, the recent FDA acceptance of Vanda’s BLA for imsidolimab — for which ANAB retains an exclusive global license — adds a second potential near-term catalyst, as approval in late 2026 could trigger milestone payments and initiate royalty streams from a rare disease product with premium pricing and limited competition, diversifying ANAB’s revenue base beyond GSK-dependent royalties.
The legal dispute with GSK over Jemperli royalties, while headline-grabbing, may actually serve to clarify and strengthen ANAB’s contractual position rather than undermine it, as the company’s countersuit alleges that GSK/Tesaro violated exclusivity terms by engaging in trials of competing PD-1 inhibitors like Keytruda and failed to maximize Jemperli’s commercial potential — claims that, if substantiated, could not only defend against the breach allegations but potentially open avenues for additional compensation or contractual remedies. Importantly, the court is scheduled to hear ANAB’s motion to dismiss by early March 2026, with a trial set for July 2026, meaning a resolution is likely within the next 12–18 months, reducing uncertainty far sooner than the market may be pricing in. Even in the unlikely event that some aspects of the agreement are modified, the core royalty structure — particularly the tiered rates tied to sales thresholds — is deeply embedded in the original 2014 contract and supported by patent life extending into the mid-2030s, making it highly resilient to unilateral changes. Moreover, GSK has a strong incentive to settle or prevail in a way that preserves the commercialization of Jemperli, as discontinuing or undermining the product would harm its own oncology franchise and contradict its public commitments to invest in immunotherapy; thus, any outcome is likely to maintain the economic value of the royalty stream to ANAB. The market may be overreacting to the litigation noise while ignoring the underlying strength of the asset: Jemperli’s sales have been growing steadily, supported by FDA approvals in endometrial cancer with dMMR/MSI-H status and ongoing trials in earlier lines of therapy, suggesting that royalty income could surpass current expectations even under a conservative scenario.

AnaptysBio (ANAB) holds a strategically valuable royalty interest in Jemperli through its 2014 agreement with Tesaro (now GSK Oncology), which entitles it to tiered royalties ranging from 8% on annual net sales below $1 billion to 25% on sales exceeding $2.5 billion, with payments continuing at least until key patents expire in 2035 in the U.S. and 2036 in the EU. Despite the ongoing legal dispute, Jemperli has demonstrated strong commercial momentum in oncology, particularly in endometrial cancer, with recent data showing continued adoption in both monotherapy and combination regimens, suggesting that sales are likely to grow significantly over the next several years. Given that GSK has not disputed the validity of the royalty structure in its filings and continues to commercialize Jemperli globally, the legal challenge appears to be a negotiating tactic rather than a fundamental threat to the underlying agreement, meaning ANAB is likely to retain its right to receive royalties regardless of the litigation outcome. The market may be underestimating the long-term cash flow potential from this asset, especially if Jemperli achieves blockbuster status — at $2 billion in annual net sales, ANAB would receive approximately $240 million annually in royalties (12% on the first $1B and 20% on the next $1B), a figure that could grow further with label expansions into other PD-1 responsive tumors such as microsatellite instability-high (MSI-H) cancers or gastric cancer, which are actively being explored in GSK’s pipeline. Furthermore, the recent FDA acceptance of Vanda’s BLA for imsidolimab — for which ANAB retains an exclusive global license — adds a second potential near-term catalyst, as approval in late 2026 could trigger milestone payments and initiate royalty streams from a rare disease product with premium pricing and limited competition, diversifying ANAB’s revenue base beyond GSK-dependent royalties.
The legal dispute with GSK over Jemperli royalties, while headline-grabbing, may actually serve to clarify and strengthen ANAB’s contractual position rather than undermine it, as the company’s countersuit alleges that GSK/Tesaro violated exclusivity terms by engaging in trials of competing PD-1 inhibitors like Keytruda and failed to maximize Jemperli’s commercial potential — claims that, if substantiated, could not only defend against the breach allegations but potentially open avenues for additional compensation or contractual remedies. Importantly, the court is scheduled to hear ANAB’s motion to dismiss by early March 2026, with a trial set for July 2026, meaning a resolution is likely within the next 12–18 months, reducing uncertainty far sooner than the market may be pricing in. Even in the unlikely event that some aspects of the agreement are modified, the core royalty structure — particularly the tiered rates tied to sales thresholds — is deeply embedded in the original 2014 contract and supported by patent life extending into the mid-2030s, making it highly resilient to unilateral changes. Moreover, GSK has a strong incentive to settle or prevail in a way that preserves the commercialization of Jemperli, as discontinuing or undermining the product would harm its own oncology franchise and contradict its public commitments to invest in immunotherapy; thus, any outcome is likely to maintain the economic value of the royalty stream to ANAB. The market may be overreacting to the litigation noise while ignoring the underlying strength of the asset: Jemperli’s sales have been growing steadily, supported by FDA approvals in endometrial cancer with dMMR/MSI-H status and ongoing trials in earlier lines of therapy, suggesting that royalty income could surpass current expectations even under a conservative scenario.

▼ Bear case

AnaptysBio (ANAB) faces significant near-term uncertainty due to the escalating legal dispute with GSK over the Jemperli royalty agreement, where GSK’s subsidiary Tesaro has accused ANAB of breaching the 2014 contract by allegedly failing to support development and commercialization efforts, a claim that, if successful, could allow GSK to terminate the license, halve future royalty and milestone payments, and secure a permanent license to Jemperli — directly threatening one of ANAB’s few near-term revenue sources. The company’s countersuit alleges that GSK interfered by favoring its own antibody-drug conjugate programs and that Tesaro violated exclusivity by testing rival PD-1 drugs like Keytruda, but these claims remain unproven and are subject to judicial interpretation, meaning the outcome is far from certain and could result in a material adverse change to the royalty structure if the court sides with GSK on key contractual terms such as exclusivity or commercialization obligations. With a trial scheduled for July 14–17, 2026, and no recent earnings call transcript available to gauge management’s confidence or provide updated financial guidance, investors are left in the dark about how ANAB is assessing the financial impact of this dispute, raising concerns that the company may be downplaying risks or lacks sufficient visibility into potential cash flow disruptions.
Even if ANAB prevails in the litigation, the market may be overestimating the durability and growth trajectory of Jemperli royalties, as the drug faces intense competition in the crowded PD-1 inhibitor space from established players like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, both of which have broader indications, larger clinical datasets, and stronger commercial infrastructure — factors that have limited Jemperli’s uptake despite its approval in dMMR/MSI-H endometrial cancer. While Jemperli has shown activity in certain niches, its sales growth has been modest relative to blockbuster expectations, and there is limited evidence of imminent label expansions that would significantly increase its addressable patient pool, calling into question whether it will ever reach the higher sales tiers ($1.5B–$2.5B+) needed to trigger the 20% or 25% royalty rates that underpin ANAB’s bullish thesis. Furthermore, the reliance on a single commercial partner (GSK) for a material portion of potential income creates concentration risk, especially given GSK’s shifting strategic priorities toward oncology areas like cell therapy and antibody-drug conjugates, which may result in reduced promotional focus on Jemperli over time. The recent FDA acceptance of Vanda’s BLA for imsidolimab, while scientifically promising, does not yet translate into near-term value for ANAB, as any milestones or royalties are contingent on approval (target date December 12, 2026), successful commercial launch, and market uptake in an ultra-rare disease (GPP) with prevalence estimates as low as 2–124 cases per million — meaning peak sales are unlikely to exceed a few hundred million dollars annually, and even then, ANAB’s share would be a fraction of that after accounting for Vanda’s commercialization efforts and potential profit-sharing terms embedded in the license agreement.

AnaptysBio (ANAB) faces significant near-term uncertainty due to the escalating legal dispute with GSK over the Jemperli royalty agreement, where GSK’s subsidiary Tesaro has accused ANAB of breaching the 2014 contract by allegedly failing to support development and commercialization efforts, a claim that, if successful, could allow GSK to terminate the license, halve future royalty and milestone payments, and secure a permanent license to Jemperli — directly threatening one of ANAB’s few near-term revenue sources. The company’s countersuit alleges that GSK interfered by favoring its own antibody-drug conjugate programs and that Tesaro violated exclusivity by testing rival PD-1 drugs like Keytruda, but these claims remain unproven and are subject to judicial interpretation, meaning the outcome is far from certain and could result in a material adverse change to the royalty structure if the court sides with GSK on key contractual terms such as exclusivity or commercialization obligations. With a trial scheduled for July 14–17, 2026, and no recent earnings call transcript available to gauge management’s confidence or provide updated financial guidance, investors are left in the dark about how ANAB is assessing the financial impact of this dispute, raising concerns that the company may be downplaying risks or lacks sufficient visibility into potential cash flow disruptions.
Even if ANAB prevails in the litigation, the market may be overestimating the durability and growth trajectory of Jemperli royalties, as the drug faces intense competition in the crowded PD-1 inhibitor space from established players like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, both of which have broader indications, larger clinical datasets, and stronger commercial infrastructure — factors that have limited Jemperli’s uptake despite its approval in dMMR/MSI-H endometrial cancer. While Jemperli has shown activity in certain niches, its sales growth has been modest relative to blockbuster expectations, and there is limited evidence of imminent label expansions that would significantly increase its addressable patient pool, calling into question whether it will ever reach the higher sales tiers ($1.5B–$2.5B+) needed to trigger the 20% or 25% royalty rates that underpin ANAB’s bullish thesis. Furthermore, the reliance on a single commercial partner (GSK) for a material portion of potential income creates concentration risk, especially given GSK’s shifting strategic priorities toward oncology areas like cell therapy and antibody-drug conjugates, which may result in reduced promotional focus on Jemperli over time. The recent FDA acceptance of Vanda’s BLA for imsidolimab, while scientifically promising, does not yet translate into near-term value for ANAB, as any milestones or royalties are contingent on approval (target date December 12, 2026), successful commercial launch, and market uptake in an ultra-rare disease (GPP) with prevalence estimates as low as 2–124 cases per million — meaning peak sales are unlikely to exceed a few hundred million dollars annually, and even then, ANAB’s share would be a fraction of that after accounting for Vanda’s commercialization efforts and potential profit-sharing terms embedded in the license agreement.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password